1 Autoantigen profiling reveals a shared post-COVID signature in fully recovered and Long

2 COVID patients

- 3
- 4 Aaron Bodansky,¹ Chung-Yu Wang,² Aditi Saxena, ² Anthea Mitchell, ² Saki Takahashi,³ Khamal
- 5 Anglin,⁴ Beatrice Huang,³ Rebecca Hoh,³ Scott Lu,⁴ Sarah A. Goldberg,⁴ Justin Romero,³ Brandon
- 6 Tran,³ Raushun Kirtikar,³ Halle Grebe,³ Matthew So,³ Bryan Greenhouse,³ Matthew S.
- 7 Durstenfeld,⁵ Priscilla Y. Hsue,⁵ Joanna Hellmuth,⁶ J. Daniel Kelly,⁴ Jeffrey N. Martin,⁴ Mark S.
- 8 Anderson,^{7,8} Steven G. Deeks,³ Timothy J. Henrich,⁹ Joseph L. DeRisi,² Michael J. Peluso³
- 9
- 10 1 Division of Pediatric Critical Care Medicine, University of California, San Francisco, San
- 11 Francisco, CA, USA
- 12 2 Chan Zuckerberg Biohub, San Francisco, CA, USA
- 13 3 Division of HIV, Infectious Diseases, and Global Medicine, University of California, San
- 14 Francisco, San Francisco, CA, USA
- 15 4 Department of Epidemiology and Biostatistics, University of California, San Francisco, San
- 16 Francisco, CA, USA
- 17 5 Division of Cardiology, University of California, San Francisco, San Francisco, CA, USA
- 18 6 Department of Neurology University of California, San Francisco, San Francisco, CA, USA
- 19 7 Diabetes Center, University of California, San Francisco, San Francisco, CA, USA
- 20 8 Department of Medicine, University of California, San Francisco, San Francisco, CA, USA
- 21 9 Division of Experimental Medicine, University of California, San Francisco, San Francisco, CA,
- 22 USA
- 23
- 24
- 25

26	Corresponding Author:	Michael Peluso, MD
27		Division of HIV, Infectious Diseases, and Global Medicine
28		University of California, San Francisco
29		San Francisco, CA, USA
30		Email: michael.peluso@ucsf.edu
31		

- 32 Keywords: SARS-CoV-2, COVID-19, post-acute sequelae of SARS-CoV-2 infection (PASC),
- 33 Long COVID, autoreactivity, autoimmunity, autoantigen

34 ABSTRACT

35 Some individuals do not return to baseline health following SARS-CoV-2 infection, leading to a 36 condition known as Long COVID. The underlying pathophysiology of Long COVID remains unknown. Given that autoantibodies have been found to play a role in severity of COVID infection 37 and certain other post-COVID sequelae, their potential role in Long COVID is important to 38 39 investigate. Here we apply a well-established, unbiased, proteome-wide autoantibody detection 40 technology (PhIP-Seq) to a robustly phenotyped cohort of 121 individuals with Long COVID, 64 41 individuals with prior COVID-19 who reported full recovery, and 57 pre-COVID controls. While a distinct autoreactive signature was detected which separates individuals with prior COVID 42 infection from those never exposed to COVID, we did not detect patterns of autoreactivity that 43 44 separate individuals with Long COVID relative to individuals fully recovered from SARS-CoV-2 infection. These data suggest that there are robust alterations in autoreactive antibody profiles 45 46 due to infection; however, no association of autoreactive antibodies and Long COVID was 47 apparent by this assay.

49 BACKGROUND

Some individuals do not fully return to baseline health following SARS-CoV-2 infection and experience ongoing morbidity following the acute phase of COVID-19 (1, 2). There is now intense interest in determining the underlying mechanisms of Long COVID, one type of post-acute sequelae of SARS-CoV-2 infection (PASC) characterized by symptoms that newly developed or worsened following infection that cannot be clearly attributed to another cause (3). Immune dysregulation, including the generation of antibodies against self antigens, has been suggested as one potential driver of Long COVID that warrants further investigation (4, 5).

58 Acute SARS-CoV-2 infection is associated with the generation of autoreactive antibodies,

59 particularly among individuals with severe disease requiring hospitalization (6–8). For example,

one study of 147 individuals hospitalized with COVID-19 found that autoantibodies associated with

61 connective tissue diseases and anti-cytokine antibodies were identified in 50% of samples, and

62 tracked with the humoral response to SARS-CoV-2 infection (7). Furthermore, multiple studies

63 have described the contribution of likely pre-existing anti-interferon antibodies to vaccine

64 breakthrough infections and severe manifestations of COVID-19, including death (9–12).

65

Although much work has been done exploring the potential virologic and immunologic factors 66 67 driving Long COVID, the evaluation of autoantibodies in this condition has been more limited. Measurement of anti-nuclear antibodies on standard clinical tests has yielded mixed findings, with 68 69 some studies identifying a high prevalence of antinuclear antibodies (ANAs) among those with 70 Long COVID (13–15) and other studies finding low prevalence consistent with ANA positivity in 71 the general population (16–18). Although perturbations in interferon signaling pathways have been 72 suggested as one potential mechanism of Long COVID (4, 15), anti-interferon antibodies have not been identified in most individuals outside of those who had severe acute infection (16). This is 73

consistent with other post-acute sequelae of COVID such as multisystem inflammatory syndrome

in children (MIS-C), which also has no association with anti-interferon antibodies (19).

76

- The identification of previously reported autoantibodies can be performed using targeted assays. However, identifying the full range of novel autoreactive antibodies, whether they are pathological or not, requires technologies capable of high-throughput, unbiased, proteome-wide screens. In this study, we screened a cohort of individuals with prior SARS-CoV-2 infection, many of whom met clinical criteria for Long COVID, to determine whether a consistent pattern of autoreactivity could be identified. This same technology has been previously utilized to discover novel autoantibodies in a wide range of disease contexts (20–23).
- 85 **RESULTS**

86 Distinct set of autoreactive antibodies in individuals with prior SARS-CoV-2 infection 87 We employed a previously published proteome-wide approach using a T7 phage-display assay 88 with immunoprecipitation and next-generation sequencing (PhiP-Seq) (20-24). We tested sera from 185 otherwise healthy individuals with prior SARS-CoV-2 infection in parallel to sera from 57 89 90 otherwise healthy individuals collected prior to the known existence of COVID-19 (pre-COVID). 91 Using an unbiased analysis, we identified a distinct pattern of autoreactivity which effectively 92 classifies individuals with prior SARS-CoV-2 infection from individuals not yet exposed to the virus 93 with a logistic regression AUC of 0.90 (Figure 1A). The protein targets from which these enriched 94 immunoprecipitated peptides were derived are widely varied and lack any apparent shared 95 biological functions or cell type (Figure 1B). Among the identified targets, a single peptide derived from ARHGAP31 (Figure 2A) displayed the greatest amount of enrichment with 22% of individuals 96 97 with prior SARS-CoV-2 infection yielding enrichment greater than 6 standard deviations of the

98 mean of the pre-COVID controls. No difference in enrichment was observed for those diagnosed

99 with Long COVID with respect to Post-COVID (Figure 2B).

100

To investigate whether the ARHGAP31 peptide enrichment could be the result of cross-reactivity
with antibodies directed against SARS-CoV-2 proteins, we performed a multiple sequence
alignment of this 49-amino acid fragment against the full SARS-CoV-2 proteome. A region within
the SARS-CoV2 Orf1a polyprotein was identified with considerable physico-chemical similarity to
a portion of the autoreactive fragment in ARHGAP31(Jalview Version 2;Figure 2C), supporting the
notion that the observed human peptidome peptide enrichments in post-COVID samples are being
driven by anti-SARS-CoV-2 antibodies.

109 ARHGAP31 is most highly expressed in neuronal cells, Langerhans cells, and endothelial cells

110 (Human Protein Atlas, proteinatlas.org). We were unable to identify any clinical differences

between individuals with and without ARHGAP31 autoreactivity, such as differences in frequencyof neurologic symptoms.

113

114 Post-COVID autoreactivities are not enriched in individuals with Long COVID

115 To assess whether autoreactive antibodies present in individuals following SARS-CoV-2 infection 116 are associated with Long COVID, we compared the distribution of the enriched post-COVID peptides amongst the 121 individuals with Long COVID and the 64 individuals with prior SARS-117 CoV-2 infection but without Long COVID (Convalescent COVID). The 20 most enriched proteins 118 119 with at least 5-fold greater than background (defined as fold-change over mock-IP with protein 120 A/G beads) were compared (Figure 3). Seventeen of the 20 enriched proteins were present in 121 both Long COVID and Convalescent COVID, and none of these enrichments was observed in any 122 of the pre-COVID controls. Overall, there was no significant differences in enrichment between

Long COVID and Convalescent COVID. Peptides derived from three proteins, TMED10, FUCA1, and POL2RK, were only observed in Long COVID, however these were infrequently observed.

125

126 Subgroup analyses were performed to determine whether any of these observed autoreactivities were enriched in particular symptom-defined phenotypes of Long COVID. These include 127 128 cardiopulmonary (cough, shortness of breath, chest pain, palpitations, and fainting), central 129 neurologic symptoms (problems with vision, headache, difficulty with concentration or memory, 130 dizziness, and difficulty with balance), any neurologic symptom (problems with vision, headache, 131 difficulty with concentration or memory, dizziness, difficulty with balance, trouble with smell or 132 taste, phantosmia, or paresthesia), gastrointestinal (diarrhea, constipation, nausea, vomiting, loss 133 of appetite, and abdominal pain), musculoskeletal (back pain, muscle pain, pain in the arms, legs, 134 or joints), and upper respiratory (runny nose and sore throat).

135

The peptide enrichments from individuals with particular Long COVID phenotypes were compared 136 137 to the enrichments from individuals with Convalescent COVID (no Long COVID symptoms) using 138 a one-sided Kolmogorov-Smirnov test. None of the top 20 autoantibodies were enriched in severe 139 Long COVID, and only 3 autoantibodies were statistically increased in any phenotype: TTF2 and 140 KDM3B in those with cardiopulmonary symptoms and FUCA1 in those with upper respiratory 141 symptoms (Figure 4A). However, using a strict cutoff of 6 standard deviations above the pre-142 COVID controls to determine positivity, none of these autoantibodies was phenotype specific. By 143 looking at the distribution of these antibodies in Long COVID patients with given sub-phenotype 144 relative to the remaining Long COVID patients and all convalescent COVID patients, it was 145 apparent that the statistical significance in a particular phenotype was driven by either a single 146 individual with extremely high autoantibody signal in the case of KDM3B and TTF2, or higher group signal but not meeting the positive threshold cutoff in the case of FUCA1 (Figure 4B). 147

148 Absence of Long COVID specific autoreactivities

149 In addition to analyzing the distribution of post-COVID autoreactive peptide enrichments, we also 150 performed additional analyses to detect those enrichments which might be present only in Long COVID or particular subcategories of Long COVID. To feature-weight enriched peptides, we 151 applied logistic regressions to the degree of enrichment for each individual with Long COVID and 152 153 each individual Long COVID symptom phenotype versus enrichment from convalescent COVID patients who did not have the particular symptoms. We included all previously discussed symptom 154 155 phenotypes, as well as individuals with difficulty concentrating, worsened quality of life, new depression, and generalized anxiety disorder. We were unable to identify a set of enriched 156 157 proteins specific to any of these groups of patients which could effectively distinguish the cohort 158 from controls, as the best receiver operating characteristic (ROC) area under the curve (AUC) was 159 0.67, and the mean AUC was 0.44 (Supplement 1).

160

161 **DISCUSSION**

162 Autoimmunity has been proposed as one potential mechanism driving Long COVID. We applied 163 an unbiased, proteome-wide, validated approach to assess associations between antibody 164 autoreactivity and clinical phenotype. A clear and robust difference in autoreactivity was detected between those infected with SARS-CoV-2 and pre-COVID controls. This difference was 165 166 constituted by peptides from diverse and varied proteins, most of which are intracellular, suggesting that the origin of the differential enrichment is due to cross-reactivity with SARS-CoV-2 167 168 directed antibodies in those that were exposed. A sequence comparison between a peptide from 169 the most enriched protein, ARHGAP31, and Orf1a of SARS-CoV-2 supports this notion, but 170 orthogonal validation through fine-scale epitope mapping and antibody cloning would be required 171 to demonstrate this conclusively. While the clinical significance of incidental autoreactivity due to 172 the humoral immune response to SARS-CoV-2 remains largely unknown, prior studies have

identified cross reactive autoantibodies in severe sequelae of SARS-CoV-2 infection, including
 those that develop severe neurological symptoms (Song et al., 2021). Understanding the clinical
 consequences of SARS-CoV-2 driven autoreactivity deserves further attention, perhaps through
 long-term longitudinal studies.

177

We found no association to support the hypothesis that autoreactivity, as detected in this assay, contributes to Long COVID. Despite numerous successes, PhIP-seq possesses a number of limitations. Because the T7 phage displayed peptides are only 49 amino acids, the assay inherently detects mostly linear epitopes. Therefore, complex conformational, post translationally modified, or multimeric protein configurations are not predicted to be detectable by this assay, and thus these results do not completely rule out autoimmune interactions in Long COVID that are beyond the scope of PhIP-seq.

185

In addition, our classification of Long COVID and its symptom phenotypes was based exclusively on participant self-report of symptoms. It is possible that future analyses in more homogenous cohorts, particularly those with objectively measured physiologic perturbations now associated with certain Long COVID phenotypes (e.g., postural orthostasis/tachycardia, neurocognitive function deficits, abnormalities on cardiopulmonary exercise testing) may yet reveal a role of autoantibodies in at least a subset of individuals experiencing Long COVID.

192

Long COVID remains a complex clinical entity. Its causes are likely multifactorial, and there is growing consensus that different phenotypes are driven by different pathophysiologic mechanisms (2, 3). Additional work characterizing SARS-CoV-2 specific and autoreactive immune responses in large, well-characterized cohorts over time, during both the acute and post-acute phases of the illness, will be necessary to delineate the biology of Long COVID and other post-acute sequelae of

- 198 SARS-CoV-2 infection, and to lead to the development of potential interventions to treat the
- 199 millions of individuals currently affected by this condition.
- 200

201 METHODS

202 Study participants and measurements

203 Participants were volunteers in the UCSF Long-term Impact of Infection with Novel Coronavirus (LIINC) study (NCT04362150). The details of study design and measurement have been reported 204 205 previously (25). For the current analysis, we included 185 individuals with a history of nucleic acidconfirmed SARS-CoV-2 infection who had a plasma sample collected between 60 and 240 days 206 207 following initial symptom onset or, if asymptomatic, first positive SARS-CoV-2 test (Supplemental 208 Table 1). Long COVID was defined using study instruments, which have been described in detail 209 elsewhere (25). Briefly, each participant was gueried regarding the presence, severity, and 210 duration of 32 physical and mental health symptoms and quality of life. Details of their medical 211 history and COVID-19 infection and vaccination and treatment history were also recorded. 212 Symptoms that pre-dated SARS-CoV-2 infection and that were not changed following infection, as 213 well as those obviously attributed to another cause (e.g. ankle fracture), were not considered to 214 represent Long COVID. All samples included were collected prior to the subject ever receiving a SARS-CoV-2 vaccine. 215

216

Because of challenges in objectively defining Long COVID and to thoroughly explore the data in
an unbiased manner, we utilized a number of predefined case definitions in our analysis. We
constructed case definitions based on symptom presentation and quality-of-life (QOL) responses.
Symptoms case definitions include: the presence of any new or worsening symptoms since
SARS-CoV-2 infection (Long COVID); presence of 5 or more symptoms (severe Long COVID);
specific symptom groups according to organ system involvement or phenotypic cluster; and

individual symptoms when at least 25 individuals experienced the symptom. For individual and
grouped symptom outcomes, we developed 3 potential comparisons between the symptomatic
group and (1) all individuals who reported absence of the symptoms of interest, regardless of
Long COVID status (2) only individuals who were consistently asymptomatic and (3) individuals
with Long COVID but not the symptoms of interest. Severe Long COVID was compared only to
those without any reported symptoms.

229

230 We defined 6 groups of symptoms (symptom phenotypes) based on either organ system cluster. These include cardiopulmonary (cough, shortness of breath, chest pain, palpitations, and fainting). 231 232 CNS-specific (problems with vision, headache, difficulty with concentration or memory, dizziness, 233 and difficulty with balance), any neurologic symptom (problems with vision, headache, difficulty 234 with concentration or memory, dizziness, difficulty with balance, trouble with smell or taste, 235 phantosmia, or paresthesia), gastrointestinal (diarrhea, constipation, nausea, vomiting, loss of 236 appetite, and abdominal pain), musculoskeletal (back pain, muscle pain, pain in the arms, legs, or 237 joints), and upper respiratory (runny nose and sore throat).

238

Quality-of-life was assessed using the EuroQoI-5D (EQ-5D), Patient Health Questionnaire 239 240 depression scale (PHQ-8), and Generalized Anxiety Disorder scale (GAD-7). Individuals with 241 Long COVID and the lowest overall quality-of-life (QOL) score measured via the visual analogue 242 scale of the EQ-5D were compared to individuals with the highest overall QOL scores among 243 those with and without Long COVID. Individuals with responses categorized as "moderate 244 depression" on the PHQ-8 (score higher than 10) and "moderate anxiety" on the GAD-7 (score 245 higher than 9) were compared to all participants with scores indicating less severe classifications 246 than "moderate depression" and "moderate anxiety" in the following groups: (1) all participants

- regardless of Long COVID status (2) all participant without Long COVID and (3) all participants
- with Long COVID.
- In addition, we recently demonstrated associations between Long COVID and other chronic latent
- viral infections, including serologic evidence suggesting recent Epstein-Barr virus (EBV)
- reactivation (26). For this reason, we also used binary variables to create groups indicating the
- 252 presence of this condition.
- 253

254 Biospecimen collection

At each visit, whole blood was collected in EDTA tubes. Plasma was isolated and stored in -80F
until the time of analysis.

257

258 Phage Immunoprecipitation and Sequencing (PhIP-Seq)

259 PhIP-Seq was performed following our previously published vacuum-based PhIP-Seq protocol

- 260 (23) (https://www.protocols.io/view/scaled-high-throughput-vacuum-phip-protocol-
- 261 ewov1459kvr2/v1).

262

263 PhIP-Seq analysis

All analysis (except when specifically stated otherwise) was performed at the gene-level, in which 264 265 all reads for all peptides mapping to the same gene were summed, and 0.5 reads were added to each gene to allow inclusion of genes with zero reads in mathematical analyses. Within each 266 267 individual sample, reads were normalized by converting to the percentage of total reads. To 268 normalize each sample against background non-specific binding, a fold-change(FC) over mock-IP was calculated by dividing the sample read percentage for each gene by the mean read-269 270 percentage of the same gene for the AG bead only controls. This FC signal was then used for 271 side-by-side comparison between samples and cohorts. Samples which had a FC of 5 or greater

272	were considered enriched for an antibody, and samples with a FC of 6 standard deviations above
273	the mean of pre-COVID controls were considered positive for an autoantibody. FC values were
274	also used to calculate z-scores for each disease category sample by using each respective control
275	(as specified in figures and results), and for each control sample by using all remaining controls.
276	These z-scores were used for the logistic-regression feature weighting. In the case peptide-level
277	analysis, raw reads were normalized by calculating the number of reads per 100,000 reads.
278	
279	Statistical methods
280	All statistical analysis was performed in Python using the Scipy Stats package. A two-way
281	Kolmogorov-Smirnoff(KS) test was used for comparisons of FC PhIP-Seq data between groups of
282	samples, except in the case of specifically looking for those genes with increased signal only in
283	the disease-cohort in which a one-way KS test was employed. The logistic regression machine-
284	learning classifiers were performed using our recently described methods (23). Utilizing the Scikit-
285	learn package, logistic regression classifiers were applied to z-scored PhIP-Seq values from
286	individuals with a designated disease category versus the designated control. A liblinear solver
287	was used with L1 regularization, and the model was evaluated using a five-fold cross-validation (4
288	of the 5 for training, 1 of the 5 for testing).

289

290 Informed consent

Participants provided written informed consent. The study was approved by the UCSF InstitutionalReview Board.

- 294 FOOTNOTES
- 295 Acknowledgements

We are grateful to the study participants and their medical providers. We acknowledge current and 296 297 former LIINC clinical study team members Tamara Abualhsan, Andrea Alvarez, Khamal Anglin, Urania Argueta, Mireya Arreguin, Kofi Asare, Melissa Buitrago, Monika Deswal, Nicole DelCastillo, 298 Emily Fehrman, Halle Grebe, Heather Hartig, Yanel Hernandez, Rebecca Hoh, Beatrice Huang, 299 Marian Kerbleski, Raushun Kirtikar, James Lombardo, Monica Lopez, Michael Luna, Sadie 300 301 Munter, Lynn Ngo, Enrique Martinez Ortiz, Antonio Rodriguez, Justin Romero, Dylan Ryder, Ruth Diaz Sanchez, Matthew So, Celina Chang Song, Viva Tai, Alex Tang, Cassandra Thanh, Fatima 302 303 Ticas, Leonel Torres, Brandon Tran, Daisy Valdivieso, Deepshika Varma, and Meghann Williams; 304 and LIINC laboratory team members Amanda Buck. Tyler-Marie Deveau, Joanna Donatelli, Jill 305 Hakim, Nikita Iyer, Owen Janson, Brian LaFranchi, Christopher Nixon, Isaac Thomas, and 306 Keirstinne Turcios. We thank Jessica Chen, Aidan Donovan, Carrie Forman, and Rania Ibrahim 307 for assistance with data entry and review. We thank the UCSF AIDS Specimen Bank for 308 processing specimens and maintaining the LIINC biospecimen repository. We are grateful to 309 Elnaz Eilkhani and Monika Deswal for regulatory support.

310

311 Author Contributions

AB, ST, BG, JDT, JNM, SGD, TJH, JLD, and MJP designed the study. JDT, JNM, SGD, TJH, and 312 MJP designed and oversaw the LIINC cohort, with major contributions from BG, MSD, PYH, and 313 JH. KA, BH, and RH managed cohort operations. Clinical data were collected by JR, BT, RK, HG, 314 315 and MS. SL and SG managed the data and developed the clinical dataset. ST, SL, SG, and MJP 316 selected participants for inclusion in this study. Biospecimens were processed in the laboratories 317 of BG and TJH. CW, AS, and AM performed the measurements in the laboratories of MSA and 318 JLD. AB performed the data analysis. AB, TJH, JLD, and MJP wrote the first draft of the paper, 319 with input from all other authors. All authors edited the manuscript and approved the final version.

321 Funding

322 This work was supported by NIH/NIAID 3R01AI141003-03S1 and NIH/NIAID R01AI158013 (to M

- 323 Gandhi and M Spinelli), Pediatric Scientist Development Program and the Eunice Kennedy
- 324 Shriver National Institute of Child Health and Human Development (K12-HD000850 to A.
- 325 Bodansky), and Chan Zuckerberg Biohub support for J. DeRisi.

326

327 Conflicts of Interest

- 328 TJH reports grants from Merck & Co, Gilead Sciences, and Bristol-Myers Squibb, and has
- 329 provided consulting for Roche, outside the submitted work. SGD reports grants and/or personal
- 330 fees from Gilead Sciences, Merck & Co., Viiv, AbbVie, Eli Lilly, ByroLogyx, and Enochian
- Biosciences, outside the submitted work. JD reports paid compensation for consulting for the
- 332 Public Health Company and Allen & Co. MJP reports consulting fees from Gilead Sciences and
- 333 AstraZeneca, outside the submitted work. All other authors report no potential conflicts.

334

336 FIGURE LEGENDS

- 337 Figure 1: PhIP-Seq autoreactivities distinguish post-COVID sera from pre-COVID controls.
- 338 Logistic regression comparing PhIP-Seq autoreactivities in all individuals with prior COVID
- infection compared to pre-COVID controls. Barplot showing autoreactivities with the top 20 logistic
- 340 regression coefficients.
- 341
- Figure 2: Post-COVID anti-ARHGAP31 autoreactivities target specific region with similarity
 to SARS-CoV-2
- (A) Stripplots showing distribution of ARHGAP31 autoreactivities in Long COVID, individuals with
- 345 prior COVID infection but without Long COVID, and pre-COVID controls. Dotted line at 6 standard
- 346 deviations above mean of pre-COVID controls. (B) Distribution of anti-ARHGAP31 autoreactivity
- 347 signal within ARHGAP31 full length protein. One specific fragment is targeted. (C) Amino-acid
- 348 sequence of the autoreactive region of ARHGAP31 and amino-acid sequence of a region of
- 349 SARS-CoV-2 Orf1a with similarity. Shown below is the multiple sequence
- 350 alignment(ClustalOmega; asterisk=identical amino acid; colon=strongly similar properties with
- 351 Gonnet PAM 250 matrix score >0.5; period=weakly similar with Gonnet PAM 250 matrix score
- between 0 and 0,5) and strong physical-chemical conservation (JalView; amino acid physical-
- 353 chemical conservation scored on a scale of 1-11, Asterisk=score of 11 and identical amino acid,
- 354 Plus=10, all properties conserved).
- 355

Figure 3: Post-COVID autoreactivities are similarly distributed among Long COVID and controls.

Hierarchically clustered (Pearson) heatmaps showing the PhIP-Seq enrichment for the top 20
autoreactivities ranked by logistic regression coefficient in each Long COVID patient, each COVID
convalescent patient, and each pre-COVID control.

361	Figure 4: Few significantly increased autoreactivities in Long COVID symptom phenotypes.	
362	(A) Heatmap with p-values (Kolmogorov-Smirnov testing) of differences in autoantigen enrichment	
363	for all individuals with prior COVID infection with and without additional clinical factors. Top-row	
364	compares those with and without Long COVID. Lower rows show subcategories of Long COVID.	
365	(B) Stripplots showing the three autoantibodies with statistically significant enrichment in a post-	
366	COVID clinical phenotype. Dotted-lines show 6 standard-deviations above the mean of pre-	
367	COVID signal.	
368		
369	Supplemental Table 1: Characteristics of study participants.	
370	Characteristics of all study participants, stratified by Long COVID status.	
371		
372	Supplemental Figure 1: PhIP-Seq is unable to distinguish Long COVID symptom	
373	phenotypes from controls.	
374	(A) Logistic regression receiver operating characteristic (ROC) curves for Long COVID patients	
375	with different specified symptom phenotypes relative to patients previously infected with COVID	
376	without the phenotype, or (B) with and without EBV laboratory findings.	
377		
378		

379 **REFERENCES**

- 1. Nalbandian A et al. Post-acute COVID-19 syndrome [Internet]. Nat. Med. [published online]
- 381 ahead of print: March 22, 2021]; doi:10.1038/s41591-021-01283-z
- 382 2. Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and
- 383 recommendations. *Nat. Rev. Microbiol.* 2023;1–14.
- 384 3. Peluso MJ, Deeks SG. Early clues regarding the pathogenesis of long-COVID. *Trends*385 *Immunol.* 2022;43(4):268–270.
- 386 4. Proal AD, VanElzakker MB. Long COVID or Post-acute Sequelae of COVID-19 (PASC): An
- 387 Overview of Biological Factors That May Contribute to Persistent Symptoms [Internet]. *Frontiers in*
- 388 *Microbiology* 2021;12. doi:10.3389/fmicb.2021.698169
- 389 5. Peluso MJ, Donatelli J, Henrich TJ. Long-term immunologic effects of SARS-CoV-2 infection:
- 390 leveraging translational research methodology to address emerging questions. *Transl. Res.*

391 2022;241:1–12.

- 392 6. Zuo Y et al. Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19
- 393 [Internet]. Sci. Transl. Med. 2020;12(570). doi:10.1126/scitranslmed.abd3876
- 7. Chang SE et al. New-onset IgG autoantibodies in hospitalized patients with COVID-19. *Nat. Commun.* 2021;12(1):5417.
- 396 8. Woodruff MC et al. Dysregulated naïve B cells and de novo autoreactivity in severe COVID-19
- 397 [Internet]. *Nature* [published online ahead of print: August 31, 2022]; doi:10.1038/s41586-022-

398 05273-0

399 9. Bastard P et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19

400 [Internet]. *Science* 2020;370(6515). doi:10.1126/science.abd4585

- 401 10. Bastard P et al. Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected
- 402 individuals over 70 years old and account for ~20% of COVID-19 deaths [Internet]. Sci Immunol
- 403 2021;6(62). doi:10.1126/sciimmunol.abl4340
- 404 11. Vazquez SE et al. Neutralizing Autoantibodies to Type I Interferons in COVID-19
- 405 Convalescent Donor Plasma. J. Clin. Immunol. 2021;41(6):1169–1171.
- 406 12. van der Wijst MGP et al. Type I interferon autoantibodies are associated with systemic
- 407 immune alterations in patients with COVID-19. Sci. Transl. Med. 2021;13(612):eabh2624.
- 408 13. Son K et al. Circulating anti-nuclear autoantibodies in COVID-19 survivors predict long-COVID
- 409 symptoms [Internet]. Eur. Respir. J. [published online ahead of print: September 22, 2022];
- 410 doi:10.1183/13993003.00970-2022
- 411 14. Seeßle J et al. Persistent symptoms in adult patients one year after COVID-19: a prospective
- 412 cohort study [Internet]. *Clin. Infect. Dis.* [published online ahead of print: July 5, 2021];
- 413 doi:10.1093/cid/ciab611
- 414 15. Su Y et al. Multiple Early Factors Anticipate Post-Acute COVID-19 Sequelae [Internet]. *Cell*415 2022;0(0). doi:10.1016/j.cell.2022.01.014
- 416 16. Peluso MJ, Thomas IJ, Munter SE, Deeks SG, Henrich TJ. Lack of Antinuclear Antibodies in
 417 Convalescent Coronavirus Disease 2019 Patients With Persistent Symptoms. *Clin. Infect. Dis.*418 2022;74(11):2083–2084.
- 419 17. Schultheiß C et al. The IL-1β, IL-6, and TNF cytokine triad is associated with post-acute
 420 sequelae of COVID-19. *Cell Rep Med* 2022;3(6):100663.

- 421 18. Klein J et al. Distinguishing features of Long COVID identified through immune profiling
- 422 [Internet]. *medRxiv* [published online ahead of print: August 10, 2022];
- 423 doi:10.1101/2022.08.09.22278592
- 424 19. Bodansky A et al. NFKB2 haploinsufficiency identified via screening for IFNα2 autoantibodies
- 425 in children and adolescents hospitalized with SARS-CoV-2-related complications [Internet]. J.
- 426 Allergy Clin. Immunol. [published online ahead of print: December 9, 2022];
- 427 doi:10.1016/j.jaci.2022.11.020
- 428 20. Mandel-Brehm C et al. Kelch-like Protein 11 Antibodies in Seminoma-Associated
- 429 Paraneoplastic Encephalitis. N. Engl. J. Med. 2019;381(1):47–54.
- 430 21. O'Donovan B et al. High-resolution epitope mapping of anti-Hu and anti-Yo autoimmunity by
- 431 programmable phage display. *Brain Commun* 2020;2(2):fcaa059.
- 432 22. Vazquez SE et al. Identification of novel, clinically correlated autoantigens in the monogenic
- 433 autoimmune syndrome APS1 by proteome-wide PhIP-Seq [Internet]. *Elife* 2020;9.
- 434 doi:10.7554/eLife.55053
- 435 23. Vazquez SE et al. Autoantibody discovery across monogenic, acquired, and COVID-19-

436 associated autoimmunity with scalable PhIP-seq [Internet]. *Elife* 2022;11. doi:10.7554/eLife.78550

437 24. Larman HB et al. Autoantigen discovery with a synthetic human peptidome. *Nat. Biotechnol.*438 2011;29(6):535–541.

439 25. Peluso MJ et al. Persistence, magnitude, and patterns of postacute symptoms and quality of

440 life following onset of SARS-CoV-2 infection: cohort description and approaches for measurement.

- 441 In: Open forum infectious diseases. Oxford University Press US; 2022:ofab640
- 442 26. Peluso MJ et al. Impact of pre-existing chronic viral infection and reactivation on the

- 443 development of long COVID [Internet]. J. Clin. Invest. [published online ahead of print: December
- 444 1, 2022]; doi:10.1172/JCI163669









